Tigermed and Frontage Laboratories Complete Strategic Investment Agreement

Jul 30, 2014
By Applied Clinical Trials

Hangzhou Tigermed Consulting and Frontage Laboratories announced completion of the previously announced investment agreement, following approval by the China Securities and Regulatory Commission. Tigermed, a provider of outsourced clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a bioanalysis, preclinical studies, early phase clinical studies and product development services provider for biopharmaceutical organizations. The partnership establishes the presence of Tigermed's global clinical trial network. Frontage will continue to operate independently, and will retain its existing company name, management team and operations facilities.

Read the full release here.